Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

of action that inhibits growth and targets both sporulation and toxin production, REP3123 could be a future treatment option that tackles the main challenges associated with treating CDAD: high rates of relapse and new outbreaks," stated Kenneth J. Collins, Replidyne's President & CEO. "We are excited by the potential of REP3123 and look forward to its further development."

About Clostridium difficile

C. difficile is a Gram-positive anaerobic bacterium that causes C. difficile-associated disease (CDAD). According to the Centers for Disease Control and Prevention, CDAD is on the rise worldwide, both in terms of number of cases and severity of the disease. Most cases of CDAD occur in a hospital setting due to increased use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile spores. However, more recently, CDAD has been acquired in the community setting where several outbreaks with increased mortality have occurred. The emergence of an epidemic, hypervirulent C. difficile strain (BI/NAP1, 027) that produces high levels of toxins poses a real threat to public health and demands improved infection control as well as novel treatment options.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and related dis
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is proud ... Vision, Innovation, and Leadership has been awarded to Stuart ... an individual who has had a significant impact on the ... several decades. "I am honored to receive the ... Ph.D., CEO of PTC Therapeutics, Inc. "When I founded PTC ...
(Date:11/21/2014)... Ohio and MELVILLE, N.Y. ... CAH ), one of the world,s largest ... HSIC ), the world,s largest provider of ... health and medical practitioners, today announced that the companies ... one of the most comprehensive service and product offerings ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
(Date:11/21/2014)... 21, 2014 The Ohio Children’s Trust ... Ohio Chapter, American Academy of Pediatrics (Ohio AAP, ... education to parents and caregivers throughout Ohio. The new ... 30, 2015, provides $75,000 to continue the campaign that ... Trust Fund is excited to continue partnering with the ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Recently, ... and launched a wedding dress promotion for the coming ... enjoy a special offer when checking out. , The ... in 2014. The customers like the designs for the ... VogueQueen.com would not only be good for the environment, ...
(Date:11/21/2014)... In summer, when it’s hot out, ... perspire and rarely feel thirsty. As a result, less ... glasses of fresh water a day recommended for health ... Sharon Kleyne. Winter weather is often more dehydrating than ... important.     , The syndicated Sharon Kleyne ...
(Date:11/21/2014)... Recently, DressVe.com , a renowned women’s dress wholesaler ... collection of fashion accessories. Furthermore, the company has launched its ... off, on all its fashion items. Also, orders above $59 ... of the company, their wedding dresses and prom dresses are ... greatly discounted rates. , The CEO says “We are ...
(Date:11/21/2014)... 21, 2014 Even with years of experience ... learn and room for growth, participating in two recent events ... Farm’s National Convention, a networking event with the leaders of ... bringing back the latest and greatest in insurance news and ... Kirk and his team (Stacy, Anthony, Reina and Jacob) as ...
Breaking Medicine News(10 mins):Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 3Health News:Beach Wedding Dresses on Sale for the Coming Holiday Season at VogueQueen.com 2Health News:Our Bodies Need Eight Glasses of Water a Day Even in Winter Reports Fresh Water Advocate 2Health News:Our Bodies Need Eight Glasses of Water a Day Even in Winter Reports Fresh Water Advocate 3Health News:DressVe.com Announces Its 2014 Special Friday Sales 2Health News:Kirk Martin Insurance Agency Goes Local and National with State Farm 2
... adjustments to desks, chairs reduce eyestrain, poor posture, study ... a proactive approach can help reduce the level of ... have found. , Employers shouldn,t just assume that problems ... equipment including desks and chairs. It,s also important to ...
... New ... while replacing undefined media components such as hydrolysates or fetal bovine serum ("FBS") in ... ... performance of its newest CHO cell culture media supplement Zap-CHO during the ...
... Inc., a medical device company that develops technologies for ... that the first procedure in Spain utilizing its cPAX ... CE Mark earlier this year. , Dr. Alfredo Casasco, ... Nuestra Senora del Rosario, used 143cm of cPAX in ...
... , KidzPartners now available in Philadelphia County ... that it is offering comprehensive health insurance through the ... you by Health Partners, newest program, KidzPartners, has already ... to surrounding counties in the future. , ...
... ... & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 ... it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to ... ...
... China, Oct. 28 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") ... pharmaceutical products in China, today,announced that it plans to release ... the market opens. , The Company ... November 12, 2009,to discuss fiscal third quarter 2009 results. ...
Cached Medicine News:Health News:Takes a Pro to Make Offices Pain-Free 2Health News:InVitria Reports Successful Cell Culture Performance of Zap-CHO, a Defined and Cost Effective CHO Cell Culture Media Supplement 2Health News:NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 2Health News:NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 3Health News:Health Partners to Offer Health Insurance Through the Children's Health Insurance Program 2Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 2Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 3Health News:China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009 2
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... a biological material derived from ... for excellent suppleness and strength. ... ensure high levels of quality ... enhances the biocompatibility, performance and ...
Medicine Products: